Esperion Therapeutics (ESPR) Revenue (2019 - 2026)

Esperion Therapeutics has reported Revenue for 8 years, with the latest figure at $80.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 23.25% year-over-year to $80.1 million; the trailing twelve-month figure through Mar 2026 stood at $418.2 million (up 61.13% YoY), and the FY2025 full-year result was $403.1 million, up 21.31% from the prior year.
• Revenue for Q1 2026 stood at $80.1 million, down from $168.4 million in the prior quarter.
• The five-year high for Revenue was $168.4 million in Q4 2025, with the low at $18.8 million in Q4 2022.
• Historically, Revenue has averaged $59.3 million across 5 years, with a median of $51.6 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue sank 53.66% — and 2024, when it surged 466.14%.
• Esperion Therapeutics' Revenue stood at $18.8 million in 2022, then jumped by 71.38% to $32.2 million in 2023, then soared by 114.3% to $69.1 million in 2024, then soared by 143.73% to $168.4 million in 2025, then tumbled by 52.45% to $80.1 million in 2026.
• The last three Revenue figures came in at $80.1 million (Q1 2026), $168.4 million (Q4 2025), and $87.3 million (Q3 2025), per Business Quant data.